

Tumor Marker CONTROL

Look closer. Perform better. Deliver more.




TUMOR MARKER ANALYTES

HE4
CA 15-3
CA 19-9
CA 125
AFP
CEA
TOTAL PSA
FREE PSA
FERRITIN
CA 27.29*
CA 242*

*Non-spiked analytes. No claim is made for performance or stability.

Fujirebio Diagnostics, Inc.'s Tumor Marker Control, the only multi-constituent control to contain the novel biomarker HE4¹, is an assayed, bi-level tumor marker panel containing clinically relevant proportions of Free PSA and PSA-ACT^{2,3}, as well as excellent reconstitution stability. Manufactured to the highest quality standards, the Tumor Marker Control ensures accurate precision monitoring of *in-vitro* diagnostic laboratory testing procedures and techniques.



Tumor Marker CONTROL

Look closer. Perform better. Deliver more.

Typical Values

These values are provided solely for the convenience of the laboratory prior to the assessment of the control. Values were obtained from testing performed on the Abbott ARCHITECT and AxSYM Immunoassay systems except for HE4 (Fujirebio Diagnostics, Inc. EIA).

International Table of Clinical Decision, Reference, and Control Typical Values

Analyte	Reference Ranges*	Typical Range Level 1	Typical Range Level 2	Units
HE4	≤150 pM ⁴	50.0 – 100.0	450 – 850	pM
CA 15-3	<30 U/mL ⁵	11.9 – 22.1	105 – 195	U/mL
CA 125	<35 U/mL ⁵	17.5 – 32.5	280 – 520	U/mL
CA 19-9	<37 U/mL ⁵	39.2 – 72.8	431 – 800 ⁶	U/mL
AFP	<10.0 µg/L ⁵	15.4 – 28.6	193 – 344	µg/L
CEA	Non-Smokers <3.0 µg/L ⁵ & Smokers <5.0 µg/L ⁵	3.5 – 6.5	42.0 – 78.0	µg/L
TOTAL PSA	<4.0 µg/L ⁵	2.3 – 4.2	21.0 - 39.0	µg/L
FREE PSA	≤25% ⁵	≥ 1.0	7.0 – 19.0	µg/L
FERRITIN	Male 20-250 µg/L ⁵ Female 10-120 µg/L ⁵	31.5 – 75.0	280 – 520	µg/L

* It is recommended that each laboratory establish its own reference ranges for the population of interest.

1 Fujirebio Diagnostics, Inc. HE4 EIA

2 Lija H, Christensson A, Dahlén U, Matikainen M-T, Nilsson O, Pattersson K, Lövgren T. (1991). Prostatic-specific antigen in serum occurs predominately in complex with α1-antichymotrypsin. *Clin Chem* 37:1618-1625.

3 Lija H, Ulmert D, Vickers AJ. Prostatic specific antigen and prostate cancer: prediction, detection, and monitoring. *Nature Reviews Cancer* 2008;8:268-278.

4 Fujirebio Diagnostics AB Göteborg, Sweden. HE4 EIA Assay Insert, 404-10, 2008-09, F5907, r1.

5 Wu A. Tietz Clinical Guide To Laboratory Tests. St. Louis: W. B. Saunders Company, 2006. Print.

6 Higher values as seen with Abbott ARCHITECT assay.

Tumor Marker Multi-Constituent Control: 100% Human Sera Matrix

P/N 108-20

Tumor Marker Control Level 1 (lyophilized):
Tumor Marker Control Level 2 (lyophilized):

3 x 3 mL
3 x 3 mL

Stability (unopened vial):
18 months at 2-8°C

Reconstituted:

All analytes will be stable for 60 days when stored at ≤-20°C, 14 days at 2-8°C for most analytes with the following exception: Free PSA will be stable for 7 days Sustains 9 freeze/thaw cycles

For more information visit:
www.fdimcc.com

Please refer to current lot number package inserts for assigned values and stability claims.



Corporate Headquarters:

Fujirebio Diagnostics Inc.
201 Great Valley Parkway
Malvern, PA 19355-1307
USA

+1 888 499 9998 phone
+1 610 240 3949 fax
info@fdi.com email
www.fdi.com website

Manufactured by:

Fujirebio Diagnostics AB
Elof Lindälvs gata 13
SE-414 55 Göteborg
Sweden

+46 31 85 70 30 phone
+46 31 85 70 40 fax
order@fdab.com email
www.fdab.com website